Adis Journal Podcasts

Author: Adis

Listen to podcasts with key opinion leaders in multiple therapy areas, discussing hot topics including topic overviews, expert opinions and conference overviews. Brought to you by the Adis Journals Group, part of Springer Nature. The primary audience for these podcasts are healthcare professionals, and are published and citable through the journals.
Be a guest on this podcast

Language: en

Genres: Health & Fitness, Life Sciences, Medicine, Science

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it

Get all podcast data

Listen Now...

Overcoming Hyperkalaemia as a Barrier to Achieving Optimal RAASi Therapy in Individuals with Cardiorenal Disease
Wednesday, 25 March, 2026

Overcoming Hyperkalaemia as a Barrier to Achieving Optimal RAASi Therapy and Cardiorenal Protection in Individuals with Cardiorenal Disease: A Podcast Discussion This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-026-03518-2. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access. This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.